FDA Clearance of Faster Interpretation Time of Chromogenic MRSASelect™
Bio-Rad now have FDA clearance for a faster interpretation time of its existing MRSASelect™ test, a chromogenic medium that is used for the rapid screening of MRSA (methicillin-resistant Staphylococcus aureus). With high sensitivity and specificity as well as rapid and direct identification, the MRSASelect test can now identify MRSA carriers in as little as 18 hours. Bio-Rad received FDA clearance in the U.S. to market its MRSASelect test with the new interpretation time in June. The test was originally introduced in the U.S. in October 2007. |
NOTE: This item is from our 'historic' database and may contain information which is not up to date.
Source : Bio-Rad Laboratories View Company Information
Posted on September 16, 2008